0001589150 false --09-30 2022 Q3 0001589150 2021-10-01 2022-06-30 0001589150 2022-07-17 0001589150 2022-06-30 0001589150 2021-09-30 0001589150 us-gaap:SeriesAPreferredStockMember 2022-06-30 0001589150 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2022-06-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesMMember 2022-06-30 0001589150 RGBP:SeriesMMember 2021-09-30 0001589150 RGBP:SeriesNCMember 2022-06-30 0001589150 RGBP:SeriesNCMember 2021-09-30 0001589150 2022-04-01 2022-06-30 0001589150 2021-04-01 2021-06-30 0001589150 2020-10-01 2021-06-30 0001589150 RGBP:PreferredStockSeriesAMember 2020-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2020-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2020-09-30 0001589150 us-gaap:CommonStockMember 2020-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2020-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001589150 us-gaap:RetainedEarningsMember 2020-09-30 0001589150 RGBP:ContributedCapitalMember 2020-09-30 0001589150 2020-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2020-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2020-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2020-12-31 0001589150 us-gaap:CommonStockMember 2020-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2020-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001589150 us-gaap:RetainedEarningsMember 2020-12-31 0001589150 RGBP:ContributedCapitalMember 2020-12-31 0001589150 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-03-31 0001589150 us-gaap:CommonStockMember 2021-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001589150 us-gaap:RetainedEarningsMember 2021-03-31 0001589150 RGBP:ContributedCapitalMember 2021-03-31 0001589150 2021-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2021-09-30 0001589150 us-gaap:CommonStockMember 2021-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2021-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001589150 us-gaap:RetainedEarningsMember 2021-09-30 0001589150 RGBP:ContributedCapitalMember 2021-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2021-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-12-31 0001589150 us-gaap:CommonStockMember 2021-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001589150 us-gaap:RetainedEarningsMember 2021-12-31 0001589150 RGBP:ContributedCapitalMember 2021-12-31 0001589150 2021-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-03-31 0001589150 us-gaap:CommonStockMember 2022-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001589150 us-gaap:RetainedEarningsMember 2022-03-31 0001589150 RGBP:ContributedCapitalMember 2022-03-31 0001589150 2022-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2020-10-01 2020-12-31 0001589150 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2020-10-01 2020-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001589150 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001589150 RGBP:ContributedCapitalMember 2020-10-01 2020-12-31 0001589150 2020-10-01 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-01-01 2021-03-31 0001589150 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-01-01 2021-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001589150 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001589150 RGBP:ContributedCapitalMember 2021-01-01 2021-03-31 0001589150 2021-01-01 2021-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-04-01 2021-06-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-04-01 2021-06-30 0001589150 RGBP:SeriesNCPreferredStockMember 2021-04-01 2021-06-30 0001589150 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001589150 RGBP:SeriesMPreferredStockMember 2021-04-01 2021-06-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001589150 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001589150 RGBP:ContributedCapitalMember 2021-04-01 2021-06-30 0001589150 RGBP:PreferredStockSeriesAMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-10-01 2021-12-31 0001589150 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-10-01 2021-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001589150 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001589150 RGBP:ContributedCapitalMember 2021-10-01 2021-12-31 0001589150 2021-10-01 2021-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-01-01 2022-03-31 0001589150 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-01-01 2022-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001589150 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001589150 RGBP:ContributedCapitalMember 2022-01-01 2022-03-31 0001589150 2022-01-01 2022-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-04-01 2022-06-30 0001589150 RGBP:SeriesAAPreferredStockMember 2022-04-01 2022-06-30 0001589150 RGBP:SeriesNCPreferredStockMember 2022-04-01 2022-06-30 0001589150 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001589150 RGBP:SeriesMPreferredStockMember 2022-04-01 2022-06-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001589150 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001589150 RGBP:ContributedCapitalMember 2022-04-01 2022-06-30 0001589150 RGBP:PreferredStockSeriesAMember 2021-06-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-06-30 0001589150 RGBP:SeriesNCPreferredStockMember 2021-06-30 0001589150 us-gaap:CommonStockMember 2021-06-30 0001589150 RGBP:SeriesMPreferredStockMember 2021-06-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001589150 us-gaap:RetainedEarningsMember 2021-06-30 0001589150 RGBP:ContributedCapitalMember 2021-06-30 0001589150 2021-06-30 0001589150 RGBP:PreferredStockSeriesAMember 2022-06-30 0001589150 RGBP:SeriesAAPreferredStockMember 2022-06-30 0001589150 RGBP:SeriesNCPreferredStockMember 2022-06-30 0001589150 us-gaap:CommonStockMember 2022-06-30 0001589150 RGBP:SeriesMPreferredStockMember 2022-06-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001589150 us-gaap:RetainedEarningsMember 2022-06-30 0001589150 RGBP:ContributedCapitalMember 2022-06-30 0001589150 srt:MinimumMember 2021-10-01 2022-06-30 0001589150 srt:MaximumMember 2021-10-01 2022-06-30 0001589150 2021-04-01 2022-06-30 0001589150 RGBP:ZanderTherapeuticsMember 2022-06-30 0001589150 2012-04-24 2022-06-30 0001589150 RGBP:DavidKoosMember 2022-06-30 0001589150 RGBP:DavidKoosMember 2022-06-30 0001589150 RGBP:DavidKoosMember 2021-10-01 2022-06-30 0001589150 RGBP:March82016Member 2022-06-30 0001589150 RGBP:April62016Member 2022-06-30 0001589150 RGBP:April62016Member 2022-06-20 0001589150 RGBP:October312016Member 2022-06-30 0001589150 RGBP:October3120161Member 2022-06-30 0001589150 RGBP:October3120162Member 2022-06-30 0001589150 RGBP:October3120162Member 2021-06-30 0001589150 RGBP:March132017Member 2022-06-30 0001589150 RGBP:March132017Member 2021-10-01 2022-06-30 0001589150 RGBP:March312017Member 2022-06-30 0001589150 RGBP:March3120171Member 2022-06-30 0001589150 RGBP:March3120171Member 2021-10-01 2022-06-30 0001589150 RGBP:April192017Member 2022-06-30 0001589150 RGBP:May52017Member 2022-06-30 0001589150 RGBP:May52017Member 2021-10-01 2022-06-30 0001589150 RGBP:June262017Member 2022-06-30 0001589150 RGBP:June262017Member 2021-10-01 2022-06-30 0001589150 RGBP:Sept252017Member 2022-06-30 0001589150 RGBP:Sept252017Member 2021-10-01 2022-06-30 0001589150 RGBP:Oct0317Member 2022-06-30 0001589150 RGBP:Oct0317Member 2021-10-01 2022-06-30 0001589150 RGBP:Oct1617Member 2022-06-30 0001589150 RGBP:Oct1617Member 2021-10-01 2022-06-30 0001589150 RGBP:Nov0117Member 2022-06-30 0001589150 RGBP:Nov0117Member 2021-10-01 2022-06-30 0001589150 RGBP:Nov0120172Member 2022-06-30 0001589150 RGBP:Nov0120172Member 2021-10-01 2022-06-30 0001589150 RGBP:Dec2017Member 2022-06-30 0001589150 RGBP:Dec2017Member 2021-10-01 2022-06-30 0001589150 RGBP:Feb2818Member 2022-06-30 0001589150 RGBP:Feb2818Member 2021-10-01 2022-06-30 0001589150 RGBP:July112018Member 2022-06-30 0001589150 RGBP:July112018Member 2021-10-01 2022-06-30 0001589150 RGBP:September302018Member 2022-06-30 0001589150 RGBP:September302018Member 2021-10-01 2022-06-30 0001589150 RGBP:July192019Member 2022-06-30 0001589150 RGBP:September172021Member 2022-06-30 0001589150 RGBP:September172021Member 2021-10-01 2022-06-30 0001589150 RGBP:March172022Member 2022-06-30 0001589150 RGBP:ZanderTherapeuticsMember 2019-05-30 2019-06-11 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2019-11-01 2019-11-29 0001589150 RGBP:ZanderTherapeuticsMember 2021-10-01 2022-06-30 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2021-10-01 2022-06-30 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2022-06-30 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2021-10-01 2022-06-30 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2022-06-30 0001589150 RGBP:UnrelatedPartyMember 2021-04-01 2021-06-30 0001589150 RGBP:UnrelatedPartyMember 2021-07-01 2021-09-30 0001589150 us-gaap:CommonStockMember 2022-06-30 0001589150 us-gaap:CommonStockMember RGBP:OncologyPharmaMember 2022-06-30 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-04-01 2022-04-05 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-04-01 2022-04-08 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-05-01 2022-05-16 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-06-01 2022-06-09 0001589150 RGBP:AsOriginallyPresentedMember 2021-04-01 2021-06-30 0001589150 srt:RestatementAdjustmentMember 2021-04-01 2021-06-30 0001589150 RGBP:AsRestatedMember 2021-04-01 2021-06-30 0001589150 RGBP:AsOriginallyPresentedMember 2020-10-01 2021-06-30 0001589150 srt:RestatementAdjustmentMember 2020-10-01 2021-06-30 0001589150 RGBP:AsRestatedMember 2020-10-01 2021-06-30 0001589150 RGBP:AsOriginallyPresentedMember 2021-06-30 0001589150 srt:RestatementAdjustmentMember 2021-06-30 0001589150 RGBP:AsRestatedMember 2021-06-30 0001589150 us-gaap:SubsequentEventMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-07-01 2022-07-15 0001589150 us-gaap:SubsequentEventMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-07-01 2022-07-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the quarterly period ended June 30, 2022

 

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the transition period from

 

 Commission File No. 333-191725

 

 REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

 

Nevada 45-5192997
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

4700 Spring StreetSt 304La MesaCalifornia 91942

(Address of Principal Executive Offices)

 

619 722-5505

(Issuer’s telephone number)

 

None

(Former name, address and fiscal year, if changed since last report)

 

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒   No  

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐  No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐  Large accelerated filer ☐  Accelerated filer
☐  Non-accelerated filer   Smaller reporting company
   Emerging Growth Company 

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of July 17, 2022 Regen Biopharma, Inc. had 4,970,002,832  common shares outstanding.

As of July 17, 2022 Regen Biopharma, Inc. had 439,293,406 shares of Series A Preferred Stock outstanding.

As of July 17, 2022 Regen Biopharma, Inc. had 50,000 shares of Series AA Preferred Stock outstanding.

As of July 17, 2022 Regen Biopharma, Inc. had 44,000,000 shares of Series M Preferred Stock outstanding.

As of July 17, 2022 Regen Biopharma, Inc. had 10,000 shares of Series NC Preferred Stock outstanding

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No

  1  

 

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements

                 
REGEN BIOPHARMA , INC.        
CONDENSED CONSOLIDATED BALANCE SHEETS        
         
    As of June 30, 2022
(unaudited)
  As of September 30, 2021
ASSETS        
CURRENT ASSETS                
Cash   $ 110,993     $ 727,162  
Accounts Receivable, Related Party     295,466       213,192  
Note Receivable, Related Party     5,396       5,396  
Accrued Interest Receivable     629       230  
Prepaid Expenses     27,801       48,144  
     Total Current Assets     440,286       994,124  
                 
OTHER ASSETS                
Investment Securities     26,828       198,006  
Investment Securities, Related Party     222,580       19,969  
Total Other Assets     249,408       217,975  
TOTAL ASSETS   $ 689,693     $ 1,212,099  
LIABILITIES AND STOCKHOLDERS' EQUITY                
Current Liabilities:                
Accounts payable     28,799       91,498  
Notes Payable     227       1,429,179  
Accrued payroll taxes     4,241       4,241  
Accrued Interest     691,985       954,861  
Accrued Rent             0  
Accrued Payroll     1,266,679       1,266,679  
Other Accrued Expenses     41,423       41,423  
Bank Overdraft     1,000       1,000  
Due to Investor     20,000       20,000  
Unearned Income     1,749,930       1,843,806  
Derivative Liability     3,654,003       6,892,477  
Convertible Notes Payable Less  unamortized discount     1,571,090       2,131,311  
Convertible Notes Payable, Related Parties Less  unamortized discount     10,000       21,500  
Total Current Liabilities     9,039,377       14,697,976  
Long Term Liabilities:                
Convertible Notes Payable, Related Parties Less  unamortized discount             0  
Total Long Term Liabilities                
Total Liabilities     9,039,377       14,697,976  
STOCKHOLDERS' EQUITY (DEFICIT)                
Common Stock ($.0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,920,002,832 issued and outstanding as of June 30,2022 and 4,800,000,000 authorized and 4,350,554,514 shares issued and outstanding as of September 30 ,2021.     491,999       435,054  
Preferred Stock, 0.0001 par value, 800,000,000 authorized as of June 30,2022  and September 30,2021 respectively                
Series A Preferred; 300,000,000 authorized as of September 30,2021 and 540,000,000 authorized as of June 30, 2022 439,293,406 and 431,998,817 outstanding as of  June 30,2022 and September 30, 2021 respectively     43,929       43,200  
Series AA Preferred; $0.0001 par value 600,000 authorized and 50,000 and 50,000   outstanding as of June 30,2022 and September 30,2021 respectively     5       5  
Series M Preferred; $0.0001 par value 300,000,000 authorized and  44,000,000 outstanding as of September 30,2021 and 60,000,000 authorized and 44,000,000 outstanding as of June 30, 2022     4,400       4,400  
Series NC Preferred; $0.0001 par value 20,000  authorized and 10  outstanding as of September 30, 2021 and June 30,2022 respectively     1       1  
Additional Paid in capital     11,200,998       8,644,037  
Contributed Capital     736,326       736,326  
Retained Earnings (Deficit)     (20,827,342 )     (23,348,900 )
Total Stockholders' Equity (Deficit)     (8,349,684 )     (13,485,877 )
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)   $ 689,693     $ 1,212,099  

The Accompanying Notes are an Integral Part of These Financial Statements

  2  

 

 

                                 
REGEN BIOPHARMA , INC.                
CONDENSED CONSOLIDATED  STATEMENTS OF OPERATIONS                
( Unaudited)                
                 
      Quarter Ended June 30, 2022       Quarter Ended June 30, 2021 (as restated)       Nine Months Ended June 30, 2022       Nine Months Ended June 30, 2021 (as restated)  
REVENUES                                
Revenues   $ 31,292     $ 29,206     $ 93,877     $ 29,206  
Revenues, Related Party     27,425       27,425       82,274       82,274  
TOTAL REVENUES     58,717       56,631       176,151       111,480  
                                 
COST AND EXPENSES                                
Research and Development     31,061       14,254       93,869       15,893  
Research and Development, Related Party     0       0       117,250       0  
General and Administrative     6,866       24,157       18,879       108,821  
Consulting and Professional Fees     64,700       50,711       152,979       50,711  
Rent     15,000       10,000       35,000       10,000  
Total Costs and Expenses     117,627       99,122       417,977       185,425  
                                 
OPERATING INCOME (LOSS)   $ (58,910 )   $ (42,491 )   $ (241,827 )   $ (73,945 )
                                 
OTHER INCOME & (EXPENSES)                                
Interest Income     133       96       399       96  
Interest Expense     (30,399 )     (59,569 )     (107,970 )     (198,029 )
Interest Expense attributable to Amortrization of Discount     (22,203 )     (414 )     (66,631 )     (47,063 )
Penalties     0       0       (300,000 )     0  
Unrealized Gain ( Loss) on sale of Investment Securities     161,729       (308,550 )     31,433       (308,550 )
Gain(Loss) on sale of Investment Securities             (206,900 )             (206,900 )
Gain (Loss) on derecognition of Accounts Payable     0       0       62,700       0  
Derivative Income (Expense)     66,907,817       (6,871,286 )     3,238,473       (4,546,175 )
Gain (Loss) on  Extinguishment Convertible Debt     0       0       (95,019 )     0  
TOTAL OTHER INCOME (EXPENSE)     67,017,077       (7,446,623 )     2,763,384       (5,306,621 )
                                 
NET INCOME (LOSS)   $ 66,958,166     $ (7,489,114 )   $ 2,521,557     $ (5,380,566 )
NET INCOME (LOSS) attributable to common shareholders   $ 60,931,932     $ (7,489,115 )   $ 2,294,618     $ (5,380,566 )
                                 
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE     0.01274     $ (0.0021 )   $ 0.0005     $ (0.002 )
                                 
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING     4,783,780,610       3,573,338,986       4794127177       2608298343  

The Accompanying Notes are an Integral Part of These Financial Statements

  3  

 

 

                                                                                                                   
  REGEN BIOPHARMA , INC.
  Condensed Consolidated Statement of Shareholder's Deficit
  (Unaudited)
  Nine Months Ended June 30, 2021 (as restated)
                                                       
          Series A Preferred   Series AA Preferred   Series NC Preferred   Common   Series M Preferred            
          Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Additional Paid-in Capital   Retained Earnings   Contributed Capital   Total
Balance September 30, 2020     Balance September 30, 2020     381,768,689     $ 38,177       50,000       5                   1,605,000,246     $ 160,498       44,000,000     $ 4,400     $ 8,313,876     $ (16,583,666 )   $ 731,711     $(7,334,998)
Shares issued for Debt 10/28/2020   Shares issued for Debt                                                     57,726,183       5,773                       (2,021 )                   3,752
Shares Issued For Interest 10/28/2020   Shares Issued For Interest                                                     22,339,663       2,234                       (782 )                   1,452
Shares issued for Debt 11/6/2020   Shares issued for Debt                                                     60,007,919       6,001                       (2,101 )                   3,900
Shares Issued For Interest 11/6/2020   Shares Issued For Interest                                                     23,926,234       2,393                       (838 )                   1,555
Shares issued for Debt 12/11/2020   Shares issued for Debt                                                     60,834,498       6,083                       1,217                     7,300
Shares Issued For Interest 12/11/2020   Shares Issued For Interest                                                     26,185,501       2,619                       523                     3,142
Shares issued for Debt 12/16/2020   Shares issued for Debt                                                     3,300,000       330                       99                     429
Shares Issued For Interest 12/16/2020   Shares Issued For Interest                                                     1,819,077       182                       54                     236
Shares issued for Fees 12/16/2020   Shares issued for Fees                                                     1,228,077       123                       36                     159
Shares issued for Debt 12/16/2020   Shares issued for Debt                                                     62,003,571       6,200                       (2,170 )                   4,030
Shares Issued For Interest 12/16/2020   Shares Issued For Interest                                                     26,155,352       2,616                       (916 )                   1,700
Shares issued for Debt 12/17/2020   Shares issued for Debt                                                     68,333,539       6,833                       1,367                     8,200
Shares Issued For Interest 12/17/2020   Shares Issued For Interest                                                     14,883,378       1,488                       212                     1,700
Shares issued for Debt 12/17/2020   Shares issued for Debt     20,000,437       2,000                                                                       11,000                     13,000
Shares Issued For Interest 12/17/2020   Shares Issued For Interest     12,378,732       1,238                                                                       6,808                     8,046
Shares issued for Debt 12/23/2020   Shares issued for Debt                                                     88,888,889       8,889                       7,111                     16,000
Shares Issued For Interest 12/23/2020   Shares Issued For Interest                                                     19,555,555       1,956                       1,294                     3,250
Shares issued for Debt 12/31/2020   Shares issued for Debt                                                     82,004,603       8,200                       (2,870 )                   5,330
Shares Issued For Interest 12/31/2020   Shares Issued For Interest                                                     35,832,781       3,583                       (1,254 )                   2,329
Additions to Contributed Capital Quarter ended 12/31/2020     Additions to Contributed Capital Quarter ended 12/31/2020                                                                                                     1,865     1,865
Net Loss Quarter Ended December 31,2020     Net Loss Quarter Ended December 31,2020                                                                                     1,666,367             1,666,367
Balance December 31, 2020     Balance December 31, 2020     414,147,858     $ 41,415       50,000       5                   2,260,025,066     $ 226,001       44,000,000     $ 4,400     $ 8,330,646     $ (14,917,299 )   $ 733,576     $(5,581,256)
shares issued for debt 1/28/2021   shares issued for debt                                                     85,900,000       8,590                       (3,436 )                   5,154
shares issued for interest 2/23/2021   shares issued for interest                                                     88,000,000       8,800                       (4,400 )                   4,400
shares issued for debt 2/24/2021   shares issued for debt                                                     71,430,421       7,143                       22,857                     30,000
shares issued for interest 2/24/2021   shares issued for interest                                                     11,328,865       1,133                       3,625                     4,758
shares issued for debt 3/2/2021   shares issued for debt                                                     80,928,505       8,093                       (2,833 )                   5,260
shares issued for interest 3/2/2021   shares issued for interest                                                     38,341,033       3,834                       (1,342 )                   2,492
 shares issued for debt 3/9/2021   shares issued for debt                                                     67,175,355       6,718                       (3,361 )                   3,357
shares issued for interest 3/9/2021   shares issued for interest                                                     8,824,645       882                       (441 )                   441
shares issued for debt 3/12/2021   shares issued for debt                                                     16,666,667       1,667                       (667 )                   1,000
shares issued for interest 3/12/2021   shares issued for interest                                                     95,833,333       9,583                       (3,833 )                   5,750
shares issued for debt 3/18/2021   shares issued for debt                                                     68,319,520       6,832                       (3,417 )                   3,415
shares issued for interest 3/18/2021   shares issued for interest                                                     1,680,480       168                       (84 )                   84
shares issued for debt 3/31/2021   shares issued for debt                                                     38,519,260       3,852                       (1,927 )                   1,925
shares issued for interest 3/31/2021   shares issued for interest                                                     1,480,740       148                       (74 )                   74
Additions to Contributed Capital Quarter ended 3/31/2021     Additions to Contributed Capital Quarter ended 3/31/2021                                                                                                     250     250
Net Income for the Quarter Ended March 31,2021       Net Income for the Quarter Ended March 31,2021                                                                                   442,183             442,183
Balance March 31, 2021     Balance March 31, 2021     414,147,858     $ 41,415       50,000       5       0       0       2,934,453,890     $ 293,444       44,000,000     $ 4,400     $ 8,331,313     $ (14,475,117 )   $ 733,826     $(5,070,713)
Shares issued for Debt 4/12/2021   Shares issued for Debt                                                     84,214,968       8,421                       (5,310 )                   3,111
Shares issued for interest 4/12/2021   Shares issued for interest                                                     785,032       79                       (30 )                   49
Preferred Shares issued for Services 4/13/2021   Preferred Shares issued for Services                                     10000       1                                                             1
Shares issued for Debt 4/13/2021   Shares issued for Debt                                                     26,389,990       2,639                       16,361                     19,000
Shares issued for interest 4/13/2021   Shares issued for interest                                                     6,578,052       658                       4,078                     4,736
Shares issued for Debt 4/13/2021   Shares issued for Debt                                                     58,502,448       5,850                       (2,340 )                   3,510
Shares issued for interest 4/13/2021   Shares issued for interest                                                     25,134,385       2,513                       (1,005 )                   1,508
Shares issued for Debt 4/15/2021`   Shares issued for Debt                                                     97,542,355       9,754                       (3,414 )                   6,340
Shares issued for interest 4/15/2021`   Shares issued for interest                                                     48,909,645       4,891                       (1,712 )                   3,179
Shares issued for Debt 4/15/2021`   Shares issued for Debt                                                     38,145,154       3,815                       (1,527 )                   2,288
Shares issued for interest 4/15/2021`   Shares issued for interest                                                     11,336,846       1,134                       (454 )                   680
Shares issued for Debt 4/15/2021`   Shares issued for Debt                                                     89,950,579       8,995                       (4,757 )                   4,238
Shares issued for interest 4/15/2021`   Shares issued for interest                                                     360,821       36                       (19 )                   17
Shares issued for Debt 4/16/2021`   Shares issued for Debt                                                     60,257,055       6,026                       40,974                     47,000
Shares issued for interest 4/16/2021`   Shares issued for interest                                                     10,498,830       1,050                       7,139                     8,189
Shares issued for Debt 4/21/2021   Shares issued for Debt                                                     126,423,649       12,642                       (4,987 )                   7,655
Shares issued for interest 4/21/2021   Shares issued for interest                                                     37,390,351       3,739                       (1,475 )                   2,264
Shares issued for Debt 4/28/2021   Shares issued for Debt                                                     24,445,152       2,445                       19,555                     22,000
Shares issued for interest 4/28/2021   Shares issued for interest                                                     4,339,015       434                       3,471                     3,905
Shares issued for Debt 5/3/2021   Shares issued for Debt                                                     21,792,903       2,179                       (763 )                   1,416
Shares issued for interest 5/3/2021   Shares issued for interest                                                     11,219,652       1,122                       (393 )                   729
Shares issued for Debt 5/5/2021   Shares issued for Debt                                                     18,271,120       1,827                       (640 )                   1,187
Shares issued for interest 5/5/2021   Shares issued for interest                                                     9,481,896       948                       (332 )                   616
Shares issued for Debt 5/18/2021   Shares issued for Debt                                                     33,772,000       3,377                       (1,351 )                   2,026
Contributed Capital Quarter Ended June 30, 2021     Contributed Capital Quarter Ended June 30, 2021                                                                                                     2,500     2,500
Net Loss for the Quarter Ended June 30,2021     Net Loss for the Quarter Ended June 30,2021                                                                                     (7,489,115 )           (7,489,115)
Balance June 30, 2021   Balance June 30, 2021     414,147,858     $ 41,415       50,000     $ 5       10,000     $ 1       3,780,195,788     $ 378,018       44,000,000     $ 4,400     $ 8,392,382     $ (21,964,232 )   $ 736,326     $(12,411,685)
Balance September 30, 2021   Balance September 30, 2021     431,998,817     $ 43,200       50,000     $ 5       10,000     $ 1       4,350,554,514     $ 435,054       44,000,000     $ 4,400     $ 8,644,037     $ (23,348,900 )   $ 736,326     $(13,485,877)
Shares issued for Debt 10/1/2021   Shares issued for Debt                                                     10,000,000       1,000                       99,000                     100,000
Shares issued for Interest 10/1/2021   Shares issued for Interest                                                     2,666,200       267                       26,395                     26,662
Shares issued for Debt 10/1/2021   Shares issued for Debt                                                     10,000,000       1,000                       99,000                     100,000
Shares issued for Interest 10/1/2021   Shares issued for Interest                                                     3,883,700       388                       38,449                     38,837
Shares issued for Debt 10/1/2021   Shares issued for Debt                                                     6,022,971       602                       49,398                     50,000
Shares issued for Interest 10/1/2021   Shares issued for Interest                                                     2,361,366       236                       19,367                     19,603
Shares issued for Debt 10/1/2021   Shares issued for Debt